Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Croatia

Marie Skłodowska-Curie Action · Running

INVECTA Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications

Coordinator
Ruder Boskovic Institute, Croatia
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€198k
Total cost
—
Partners
6 organisations in 4 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101129778

What the project is doing

In the project's own words, from its summary on CORDIS.

Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establishing foundation for long term collaboration.

As the use of adenoviral based platforms becomes widespread there is a pressing need to develop protocols and methodologies to define the full complement of adenovirus-host interactions, the “adenoviral interactome”, that may limit efficacy and compromise safety. Within INVECTA we aim to increase our understanding of novel low seroprevalence adenovirus vectors with respect to infectivity, structure, stability, receptor usage, tropism, and the interaction with the blood and immune system.

This knowledge will allow us to evaluate novel low seroprevalence vectors at the pre-clinical level in areas of unmet clinical need, namely cancer gene therapy and vaccination. INVECTA presents an interdisciplinary and intersectoral network in basic and translational adenovirus research which will foster transfer of knowledge, skills and technology, as well as enable training in the field of basic and applicative adenovirus biology.

To maximize knowledge sharing, INVECTA will second researchers within consortium, organize internal workshops and training sessions, and strongly encourage participation in specialized workshops, schools and conferences according to the open science model.

Topics

Who is involved

OrganisationCityCountryRole
Ruder Boskovic InstituteZagrebCroatiaCoordinator
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universidad Autonoma De MadridMadridSpainParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Accession Therapeutics LimitedOxfordUnited KingdomAssociatedpartner
Cardiff UniversityCardiffUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI